Pegasus Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Pegasus Asset Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,688	Closed	-$25K	–	73
2020 Q3	$25K	Hold	4,688	–	–	0.02%	70
2020 Q2	$28K	Hold	4,688	–	–	0.02%	69
2020 Q1	$17K	Hold	4,688	–	–	0.01%	67
2019 Q4	$30K	Buy	4,688 +188	+4%	+$2.39K	0.02%	72
2019 Q3	$66K	Sell	4,500 -188	-4%	-$3.1K	0.05%	68
2019 Q2	$69K	Hold	4,688	–	–	0.05%	67
2019 Q1	$197K	Hold	4,688	–	–	0.16%	65
2018 Q4	$195K	Buy	+4,688	New	+$211K	0.18%	66

Other funds holding FSTX

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

STC

Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pegasus Asset Management's FSTX Position: Q4 2020 in Review

Pegasus Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2020, closing a stake of 4,688 shares — an estimated $25K sold.

Pegasus Asset Management first reported a position in FSTX in Q4 2018 and held it in 8 quarters. The position peaked at $197K in Q1 2019. 21 funds tracked by Wall St. Rank hold FSTX as of Q4 2020.

Pegasus Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Pegasus Asset Management sold 4,688 F-star Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $25K.
Pegasus Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2018 and held it in 8 quarters.
Pegasus Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $197K in Q1 2019.
21 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Pegasus Asset Management's 13F filing for Q4 2020, filed 15 Jan 2021.